<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have had a recent spurt in cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (ARL) at our centre </plain></SENT>
<SENT sid="1" pm="."><plain>Most of these cases are aggressive mature B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, mainly plasmablastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (PBL) and diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Most of the PBL are extranodal in location and are mucosa-based </plain></SENT>
<SENT sid="3" pm="."><plain>We reviewed the morphological features of 34 cases of PBL </plain></SENT>
<SENT sid="4" pm="."><plain>Diagnosis was based on <z:mp ids='MP_0000002'>morphology</z:mp>, immunohistochemistry, proliferation index, HIV positive status and its preference to extranodal sites (mostly mucosa based) </plain></SENT>
<SENT sid="5" pm="."><plain>We classified PBL into three morphological subtypes (<z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> - 25, Burkitt's - 7, plasmacytic - 2) </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> cells expressed as leucocyte common antigen (LCA) in 60%, CD138 in 100%, EMA in 45% and light chain restriction in 86% cases </plain></SENT>
<SENT sid="7" pm="."><plain>CD20 was negative in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="8" pm="."><plain>Pathologists need to be aware of PBL and its various morphological subtypes as the identification of this entity from its close differentials carries major therapeutic implications </plain></SENT>
</text></document>